This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Fortrea's CTO discusses AI's expanding role in clinical trials, from discovery t...
Avoid common pitfalls in EU orphan drug market access—learn how local expertise ...
Venture capital firm Kineticos Life Sciences has launched a new biotech to take ...
Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for ...
Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for ...
Roche said its technique combines aspects of DNA synthesis and nanopore-based re...
Roche said its technique combines aspects of DNA synthesis and nanopore-based re...
Eleven children who were legally blind at birth all gained visual acuity after r...
The Trump administration is exploiting an administrative loophole to keep federa...
After announcing acquisition plans at the beginning of 2025, immunotherapeutics ...
This week on "The Top Line," we dive into several of the biggest failures in cli...
The NIH has lost two distinguished leaders as mass layoffs directed by the Trump...
Acelyrin had been all set to merge into Alumis—but a surprise offer by Concentra...
A slimmed-down BioMarin started the new year open for business, seeking to lever...
The wearable cardiac monitor maker VitalConnect has raised $100 million to help ...
After announcing acquisition plans at the beginning of 2025, immunotherapeutics ...
The company said its spatial technology will run on its current NextSeq and Nova...
BioMed X Institute is teaming up with the Barbados government in an effort to ac...
UroGen Pharma has opened another front in its attack on bladder cancer, paying I...
Incyte is sticking to its strategy this year of finding “early-stage, exotic stu...
CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendsch...
Clinical trial organization Flourish Research has made a deal with Diablo Clinic...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendsch...